Lefamulin was approved by the FDA in August 2019 for the treatment of CABP.
Commercial launch suspended due to manufacturer liquidity.
The drug comes at a time when antibiotic resistance worries are high. Here’s why it matters.
New pleuromutilin antibiotic IV and oral tablets.
Exciting and upcoming developments, years in the making.
Changes to vaccine recommendations for older adults may mean they have to pay for pneumococcal vaccine themselves.
Comorbid CVD is an independent risk factor for CAP in patients with COPD. And inhaled steroids may increase CAP risk.